BIOMAT Database Logo BIOMAT Database Logo

Biological activity of 24,24-difluoro-1 alpha, 25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone in inducing differentiation of human myeloid leukemia cells. 1983

Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda

Vitamin D compounds added to the culture medium induce differentiation of human myeloid leukemia cells (HL-60 cells) by binding to a specific cytosol receptor protein. This system provides a biologically relevant and technically simple assay to examine the relationship between molecular structure and biological activity of vitamin D compounds. Using this culture system, the biological activity of 24,24-F2-1 alpha,25(OH)2D3 and 1 alpha,25(OH)2D3-26,23-lactone was assayed. 24,24-F2-1 alpha,25(OH)2D3 was four to seven times more potent than 1 alpha,25(OH)2D3 in inducing phagocytosis and C3 rosette formation of HL-60 cells, though both compounds bound equally well to the cytosol receptor, suggesting that the defuorination at the 24-carbon position may stimulate membrane permeability of the compound. 1 alpha,25(OH)2D3-26,23-lactone, on the other hand, was only 1/200th as active as 1 alpha,25(OH)2D3. The binding affinity of the lactone for the cytosol receptor was identical with that of 1 alpha (OH)D3, suggesting that the lactone formation between the 26 and 23 positions masks the function of the 25-hydroxyl group. The binding affinity of vitamin D3 derivatives to the specific cytosol receptor of HL-60 cells was well correlated with that of intestinal cytosol protein specifically bound to 1 alpha,25(OH)2D3.

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
Calcium regulating activity of 24a-homo-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3 and 26,27-dimethyl-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3.
November 1993, Calcified tissue international,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
26,27-Diethyl-1 alpha,25-dihydroxyvitamin D3 and 24,24-difluoro-24-homo-1 alpha,25-dihydroxyvitamin D3: highly potent inducer for differentiation of human leukemia cells HL-60.
October 1987, Chemical & pharmaceutical bulletin,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
Biological activity assessment of 1 alpha,25-dihydroxyvitamin D3-26,23-lactone in the rat.
February 1984, Journal of steroid biochemistry,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
Stereochemistry of 25-hydroxyvitamin D3-26,23-lactone and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone in rat serum.
November 1981, FEBS letters,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
Biological activity of 24,24-difluoro-1,25-dihydroxyvitamin D3.
February 1983, The American journal of physiology,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
Role of kidney tissue in the production of 25-hydroxyvitamin D3-26,23-lactone and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone.
November 1980, Proceedings of the National Academy of Sciences of the United States of America,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells.
October 1981, Biochemical and biophysical research communications,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
February 1990, Journal of medicinal chemistry,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
Metabolic pathways from 1 alpha,25-dihydroxyvitamin D3 to 1 alpha,25-dihydroxyvitamin D3-26,23-lactone. Stereo-retained and stereo-selective lactonization.
May 1987, The Journal of biological chemistry,
Y Shiina, and E Abe, and C Miyaura, and H Tanaka, and S Yamada, and M Ohmori, and K Nakayama, and H Takayama, and I Matsunaga, and Y Nishii, and H F DeLuca, and T Suda
The stereochemical configuration of the natural 1 alpha,25-dihydroxyvitamin D3-26,23-lactone.
October 1985, Archives of biochemistry and biophysics,
Copied contents to your clipboard!